



PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 52529

Title: Can cyclin-dependent kinase 4/6 inhibitors convert inoperable breast cancer relapse to operability? A case report

Reviewer’s code: 03656272

Position: Editorial Board

Academic degree: MD

Professional title: Assistant Professor, Doctor

Reviewer’s country: Turkey

Author’s country: Italy

Reviewer chosen by: Ying Dou

Reviewer accepted review: 2019-12-12 06:15

Reviewer performed review: 2019-12-12 06:34

Review time: 1 Hour

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input checked="" type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer’s expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input checked="" type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input checked="" type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-223-8242
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Dear authors, My recommendations are below, Abstract: Please add a last sentence to background section about what you will present in the text. Introduction: You should give more data about neoadjuvant therapy and also phase II study of palbociclib in breast cancer. In addition, please discuss the potential benefits of palbo over chemo in neoadjuvant setting (toxicity etc..) The English structure of the manuscript should be re-checked. Please present the case in one paragraph, you don't have to split it into sections. How could you decide to give only tamoxifen, did you perform genetic analysis? Please add it to manuscript. During follow-up how did you notice the supraclavicular LAP? During physical examination? Because MRI is not a routine imaging and if it is in your institution, discuss it in text. After surgery, did you consult radiation oncology? It is a locoregional relapse and she didn't get radiation before. Discussion: Please add the references of ongoing studies from clinicaltrials.gov.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- The same title
- Duplicate publication
- Plagiarism
- No

BPG Search:

- The same title
- Duplicate publication
- Plagiarism
- No